Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib or apitolisib with abiraterone versus abiraterone in post-docetaxel castration-resistant prostate cancer
NL-OMON45198Phase 2Active, not recruiting
- Sponsor
- GABA International
- Start
- Feb 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ipatasertib, apitolisib, abiraterone and prednisone in castration-resistant prostate cancer (CRPC) (3 arms), sponsored by GABA International. Primary endpoint: Radiographic progression-free survival. Started Feb 2014; status: active, not recruiting.
02
Drugs
ipatasertibapitolisibabirateroneprednisone
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NL-OMON45198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45198.